The MFI values of CD133 and CD44 revealed that the addition of the YAP1 inhibitor to chemoimmunotherapy reduced cancer stemness in DMS114 (MFI of CD133: 32288 vs. 23123 ; MFI of CD44: 831000 vs. 185967) and H2286 (MFI of CD133: 43859 vs. 34348 ; MFI of CD44: 2610000 vs. 163408; Figures S4C, D) cells. Here, CD44 is linked to cancer.